Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Drug Design, Development and Therapy|March 4, 2015
Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppressionYimin Shao, Geheng Yuan, Junqing Zhang, et al.
Peptides|January 11, 2014
Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db miceYimin Shao, Geheng Yuan, Yan Feng, et al.
Metabolic Syndrome and Related Disorders|July 25, 2017
Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related GlomerulopathyJiao He, Geheng Yuan, Fangxiao Cheng, et al.
Diagnostic Pathology|February 26, 2020
Aberrant expression of miR-214 is associated with obesity-induced insulin resistance as a biomarker and therapeuticFangxiao Cheng, Geheng Yuan, Jiao He, et al.
Endocrine|July 4, 2024
Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERSDifei Lu, Jun Yao, Geheng Yuan, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 19, 2019
Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide InterventionFangxiao Cheng, Geheng Yuan, Jiao He, et al.
The Oncologist|May 31, 2022
Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting SystemDifei Lu, Jun Yao, Geheng Yuan, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|January 31, 2023
Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidismPeiheng Zhang, Yang Yu, Ying Gao, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|November 11, 2025
The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD RatsYimin Shao, Shengya Xu, Yuanyuan Ma, et al.
Food & Function|January 12, 2021
Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetesXiaoya Sun, Ziqiang Cao, Yuanyuan Ma, et al.
Pageof 2